Want to see JP:4888 full AI Analyst Report?
Top Page
STELLA PHARMA CORPORATION
(4888)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥384.00
▲(89.16% Upside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by weak financial performance—sharp revenue contraction, persistent large losses, and a return to negative operating/free cash flow in 2026. Technicals provide only modest support (better near-term vs 20/50DMA but weaker vs 100/200DMA and slightly negative MACD). Valuation remains challenged due to negative earnings and no dividend yield provided.
Positive Factors
High Gross Margins
Gross margins of roughly 77%-90% indicate the company retains substantial economics on each unit of revenue. If maintained, this provides room to fund commercial activity and offers operating leverage if revenue stabilizes, despite current losses.
Negative Factors
Sharp Revenue Contraction
The roughly 67% revenue decline in 2026 after a stronger 2025 demonstrates severe sales volatility and weak earnings visibility. Such instability makes planning and resource allocation harder, while reducing the revenue base available to absorb ongoing operating costs.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Gross margins of roughly 77%-90% indicate the company retains substantial economics on each unit of revenue. If maintained, this provides room to fund commercial activity and offers operating leverage if revenue stabilizes, despite current losses.
Read all positive factors
STELLA PHARMA CORPORATION (4888) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥13.70B
Dividend YieldN/A
Average Volume (3M)225.97K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth-67.40%
EPS Growth-524.23%
CountryJP
Employees47
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-22.94
Shares Outstanding37,034,100
10 Day Avg. Volume209,220
30 Day Avg. Volume225,973
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)10.64
Price to Sales (P/S)79.85
P/FCF Ratio-74.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
STELLA PHARMA CORPORATION Business Overview & Revenue Model
Company Description
Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture ther...
STELLA PHARMA CORPORATION Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
56
Neutral
Cash Flow
35
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 323.39M | 961.06M | 269.49M | 229.07M | 100.10M |
| Gross Profit | 250.56M | 828.72M | 203.69M | 192.36M | 50.73M |
| EBITDA | -742.15M | -99.06M | -723.85M | -738.35M | -726.86M |
| Net Income | -780.92M | -140.81M | -763.75M | -778.82M | -767.72M |
Balance Sheet | |||||
| Total Assets | 4.49B | 5.42B | 3.82B | 4.33B | 4.72B |
| Cash, Cash Equivalents and Short-Term Investments | 2.82B | 3.21B | 2.35B | 2.71B | 3.28B |
| Total Debt | 747.14M | 766.78M | 933.30M | 1.09B | 1.25B |
| Total Liabilities | 2.06B | 2.21B | 1.44B | 1.58B | 1.64B |
| Stockholders Equity | 2.43B | 3.21B | 2.38B | 2.75B | 3.08B |
Cash Flow | |||||
| Free Cash Flow | -345.32M | 136.50M | -887.82M | -853.07M | -1.13B |
| Operating Cash Flow | -334.51M | 140.41M | -876.84M | -827.67M | -1.08B |
| Investing Cash Flow | -15.67M | 287.58M | -9.01M | -29.93M | -350.56M |
| Financing Cash Flow | -33.28M | 725.78M | 228.25M | 291.69M | 3.46B |
STELLA PHARMA CORPORATION Technical Analysis
Positive
203.00
Price Trends
328.20
Positive
384.62
Positive
381.49
Positive
Market Momentum
12.58
Negative
69.66
Neutral
77.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Positive. The current price of 203 is below the 20-day moving average (MA) of 353.00, below the 50-day MA of 328.20, and below the 200-day MA of 381.49, indicating a bullish trend. The MACD of 12.58 indicates Negative momentum. The RSI at 69.66 is Neutral, neither overbought nor oversold. The STOCH value of 77.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4888.
STELLA PHARMA CORPORATION Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ¥36.63B | -80.35 | ― | ― | 3.43% | -53.59% | |
51 Neutral | ¥20.75B | -10.84 | ― | ― | ― | 6.10% | |
47 Neutral | ¥13.70B | -15.27 | ― | ― | -67.40% | -524.23% | |
47 Neutral | ¥39.29B | 56.85 | ― | ― | -47.32% | ― | |
44 Neutral | ¥9.34B | -7.43 | -33.61% | ― | 74.24% | -7.78% |
* General Sector Average
JP:4888
STELLA PHARMA CORPORATION
390.00
11.00
2.90%
JP:4571
NanoCarrier Co., Ltd.
100.00
-66.00
-39.76%
JP:4593
Healios KK
282.00
-254.00
-47.39%
JP:4599
StemRIM Inc.
330.00
14.00
4.43%
JP:7774
Japan Tissue Engineering Co., Ltd.
912.00
417.00
84.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.